Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20444683 | 0.79 | KDM4E (0.47) | ALDH1A1KDM4EPOLBPLAUHTT | |
| SCHEMBL21645128 | 0.78 | KDM4E (0.45) | ALDH1A1KDM4EPOLBMEN1MAPT | |
| SCHEMBL4856952 | 0.77 | PLAU (0.46) | ALDH1A1KDM4EPOLBPLAUBCAT1 | |
| SCHEMBL13146691 | 0.76 | KDM4E (0.61) | ALDH1A1KDM4EPOLBPLAUBCAT1 | |
| SCHEMBL2354952 | 0.76 | ALDH1A1 (0.61) | ALDH1A1KDM4EPOLBBCAT1GABRP | |
| SCHEMBL13097705 | 0.73 | ALDH1A1 (0.58) | ALDH1A1KDM4EPOLBBCAT1GABRP | |
| SCHEMBL3047353 | 0.72 | PLAU (0.47) | ALDH1A1KDM4EPOLBPLAUMEN1 | |
| SCHEMBL1446736 | 0.72 | PLAU (0.50) | ALDH1A1KDM4EPLAUMEN1MAPT | |
| SCHEMBL29751039 | 0.72 | PLAU (0.50) | ALDH1A1KDM4EPLAUMEN1MAPT | |
| SCHEMBL7260889 | 0.72 | PLAU (0.50) | ALDH1A1KDM4EPLAUMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068985-A1 | 1-(1-OXO-1,2-DIHYDROPHTHALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| CN-119707931-A | Intermediate and synthesis method of 1- (1-oxo-1, 2-dihydro-phthalazin-6-yl) cycloalkyl-1-carboxamide derivatives as MTA synergistic inhibitors of PRMT5 | 百济神州(北京)生物科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-113754631-B | Heteroaryl method of indole | 中国科学院理化技术研究所 | 2022-08-30 | — | — | CN | disclosed |
| CN-113754631-A | Heteroaryl method of indole | 中国科学院理化技术研究所 | 2021-12-07 | — | — | CN | disclosed |
| CN-112390755-A | Method for heteroarylation of amine | 中国科学院理化技术研究所 | 2021-02-23 | — | — | CN | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2328865-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-6953679-B2 | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050119228-A1 | METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| EP-1506178-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | ALDH1A1 1211/4885KDM4E 1161/4885POLB 3484/4885 |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | ALDH1A1 1107/4885KDM4E 3740/4885POLB 1352/4885 |
| US-20050119228-A1 | METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF | SUCNR1, SHBG, FSHR | ALDH1A1 1888/4885KDM4E 1002/4885POLB 2878/4885 |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | ALDH1A1 3219/4885KDM4E 942/4885POLB 3542/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | ALDH1A1 1051/4885KDM4E 1539/4885POLB 2574/4885 |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | ALDH1A1 3219/4885KDM4E 942/4885POLB 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.